Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry: Draft Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
October 25, 2019
February 1, 2022
956f83ff-a6ef-4206-a544-56a3e8a65ee9
Related Documents
Labeling for Biosimilar and Interchangeable Biosimilar Products
Guidance DocumentSeptember 18, 2023Center for Drug Evaluation and Research
Geriatric Information in Human Prescription Drug and Biological Product Labeling Guidance for Industry: Draft Guidance for Industry
Guidance DocumentSeptember 15, 2020Center for Drug Evaluation and Research
Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products Guidance for Industry: Draft Guidance for Industry
Guidance DocumentJuly 28, 2020Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox